Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

British J HaematologyJun 8, 2026
Real‐world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high‐risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry

Clinical Context

We think this might be relevant to the clinical guidance for IMWG Myeloma Frailty Score.

British J HaematologyJun 8, 2026
Cost‐effective analysis of teclistamab and daratumumab versus ciltacabtagene autoleucel in relapsed multiple myeloma

Clinical Context

We think this might be relevant to the clinical guidance for IMWG Myeloma Frailty Score.

British J HaematologyJun 4, 2026
Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

Clinical Context

We think this might be relevant to the clinical guidance for IMWG Myeloma Frailty Score.

IMWG Myeloma Frailty

IMWG FRAILTYGeriatric Assessment for Multiple Myeloma

Age & Comorbidity

Functional Assessment

Awaiting Age Input

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Newly diagnosed Multiple Myeloma patients, especially those > 65 years old.
To guide the starting dose of induction regimens (e.g., VRd, Dara-VMP).
To identify patients who are at high risk for treatment-related toxicities and early discontinuation.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the SLiM-CRAB Criteria, Mayo 20/2/20 (SMM), R2-ISS (Revised 2) or the Ecog Status to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

SLiM-CRAB Criteria
Mayo 20/2/20
NCCN Prostate Risk
CML ELTS Score
mrTRG
TNM 9th Ed
CNS-IPI
ROMA Score
BSA
Lung-RADS v2022
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.